Praxis stops EMBOLD study early after relutrigine shows efficacy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. IBM
4. SPCX
5. ACN
6. NVDA
7. PRIM
8. META
9. SPY
10. DPZ

Go back to Praxis stops EMBOLD study early after relutrigine shows efficacy
(NASDAQ: PRAX) Delayed: 305.46 +2.07 (0.68%)
Previous Close $303.39    52 Week High $ 
Open $298.50    52 Week Low $ 
Day High $307.65    P/E N/A 
Day Low $296.36    EPS $ 
Volume 46,638